Week In Review: Sino Biopharma Subsidiary Enters $307 Million Agreement For Rights To NASH Candidate
September 24, 2022 at 15:00 PM EDT
Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharma, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from Inventiva in a $307 million deal. Meanwhile, CASI Pharma sold its 12% stake in its partner for $34 million.
